Letter: PNPLA3, metabolic syndrome and NAFLD status in obese subjects

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|42|5|630-630

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.5, 2015-09, pp. : 630-630

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: PNPLA3, metabolic syndrome and NAFLD status in obese subjects – authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 5, 2015-09 ,pp. : 630-631

John Wiley & Sons Inc

Access to resources Recommend Favorite

PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non‐obese subjects with hepatitis C

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 10, 2015-05 ,pp. : 939-948

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: PNPLA3 and alcoholic liver disease ‐ an alert to methodological limitations

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 593-593

John Wiley & Sons Inc

Access to resources Recommend Favorite

The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children

By  

PEDIATRIC OBESITY, Vol. 10, Iss. 3, 2015-06 ,pp. : 226-233

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: PNPLA3 and alcoholic liver disease – an alert to methodological limitations. Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 594-594

John Wiley & Sons Inc

Access to resources Recommend Favorite